Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27M | $228K | $212K | — | $329K | $0.00 | — | — | — | — |
| Revenue growth | — | -82.0% | -7.2% | — | — | -100.0% | — | — | — | — |
| Operating income | -$4.91M | -$5.22M | -$5.08M | — | -$6.40M | -$23.7M | -$18.4M | -$9.22M | -$7.01M | -$7.91M |
| Operating margin | -386.0% | -2288.6% | -2397.1% | — | -1946.7% | — | — | — | — | — |
| Net income | -$5.03M | -$5.03M | -$5.04M | — | -$6.36M | -$13.3M | -$17.5M | -$8.37M | -$6.17M | -$7.19M |
| Net margin | -395.2% | -2203.7% | -2378.6% | — | -1935.3% | — | — | — | — | — |
| EPS (diluted) | -$0.57 | -$3.44 | -$1.76 | — | -$0.74 | -$1.10 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.51M | -$4.70M | -$4.62M | — | -$4.99M | -$13.7M | -$12.3M | -$6.64M | -$4.89M | -$7.32M |
| Capital expenditures | $402K | $303K | $383K | — | $4.86K | $6.15K | $5.66K | $0.00 | — | — |
| Free cash flow | -$4.91M | -$5.00M | -$5.00M | — | -$4.99M | -$13.7M | -$12.3M | -$6.64M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.42M | $4.57M | $3.37M | $5.03M | $7.21M | $7.84M | $7.09M | $5.40M | $1.00M | $10.8M |
| Total assets | $12.9M | $7.72M | $11.8M | $5.72M | $10.8M | $14.6M | $11.6M | $8.89M | $3.81M | $13.5M |
| Total liabilities | — | — | — | $462K | $1.65M | $1.53M | $2.18M | $1.84M | $1.83M | — |
| Shareholders' equity | $12.3M | $7.40M | $3.21M | $5.26M | $6.63M | $13.1M | $9.39M | $7.05M | $1.98M | $12.5M |
| Retained earnings | -$40.4M | -$45.4M | -$50.4M | -$6.73M | -$13.1M | -$26.5M | -$44.0M | -$52.4M | -$58.6M | -$65.9M |
| Shares (wtd avg diluted) | 8.83M | 1.50M | 5.33M | 7.50M | 9.62M | 13.3M | 2.38M | 2.86M | 3.20M | 5.68M |
Every figure is extracted from Edesa Biotech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.